Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study-Reference-Cited by-同舟云学术

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study

Published:2018-02-04 Issue:6 Volume:20 Page:1515-1519
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Jabbour Serge A.¹^ORCID,Frías Juan P.²^ORCID,Guja Cristian³^ORCID,Hardy Elise⁴,Ahmed Azazuddin⁵,Öhman Peter⁴

Affiliation:

1. Division of Endocrinology, Diabetes & Metabolic Diseases, Sidney Kimmel Medical College of Thomas Jefferson University; Philadelphia Pennsylvania

2. National Research Institute; Los Angeles California

3. Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University of Medicine and Pharmacy; Bucharest Romania

4. AstraZeneca; Gaithersburg Maryland

5. Apex Medical Research; Chicago Illinois

Funder

AstraZeneca

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13206/fullpdf

Reference16 articles.

1. Cardiovascular risk assessment in patients with diabetes;Bertoluci;Diabetol Metab Syndr,2017

2. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial;Gaede;Diabetologia,2016

3. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials;Karagiannis;Diabetes Obes Metab,2015

4. A review of the long-term efficacy, tolerability, and safety of exenatide once weekly for type 2 diabetes;Genovese;Adv Ther,2017

5. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis;Storgaard;PLoS One,2016

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies;Cardiovascular Diabetology;2024-03-18

2. Chemical analysis of freeze-dried seeds of Stenocereus stellatus (white tunillo) components and evaluation of their effect on prediabetes reversion in an experimental model in female Wistar rats;Food & Function;2024

3. Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide;Pharmacological Research;2024-01

4. Efficacy and safety of polyethylene glycol loxenatide in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials;Scientific Reports;2023-11-03

5. Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes;The Journal of Clinical Endocrinology & Metabolism;2023-07-22